Last edition
News about "GSK gynecological cancer trial results"
GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers
GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.
GSK Gynecological Cancer Trial Results | 14/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members